Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH
A Multicenter, Open Label, Randomized, Parallel-group Study of Efficacy and Safety of Eculizumab (JSC GENERIUM, Russia) vs. Soliris® (Alexion Pharma GmbH, Switzerland) in Patients With Paroxysmal Nocturnal Hemoglobinuria
Sponsor: AO GENERIUM
A PHASE3 clinical study on Marchiafava-Micheli Syndrome and Paroxysmal Hemoglobinuria, this trial is completed. The trial is conducted by AO GENERIUM and has accumulated 6 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AO GENERIUM
For direct contact, visit the study record on ClinicalTrials.gov .